TP53 and cancer: Many articles have proved that AZD1775, a selective and potent wee1 inhibitor, abrogated the G2 checkpoint and selectively sensitized p53 mutant cancer cells to DNA-damaging inducers, such as gemcitabine 141, cisplatin 142, and X-ray 143.